Abstract
Diseases of the liver encompass a wide variety of clinical conditions that range from mild abnormalities on liver testing to end-stage liver disease with intrahepatic and extrahepatic manifestations and complications. These also range from acute, self-limited presentations to fulminant disease with rapid liver failure to chronic, low-level disease and also to chronic liver disease that progresses slowly over time. While the history and physical signs of this broad range of clinical disorders are quite similar, often with nonspecific findings with broad-range differentials, laboratory evaluation is critical to sorting through these disease processes. It is critical for family physicians to have an understanding of liver pathology and the laboratory assessment of the hepatic system.
Similar content being viewed by others
References
Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med. 1998;338:286.
Kojaoglanian T. Hepatitis A. Pediatr Rev. 2010;31(8):348–50.
Matheny SC, Kingery JE. Hepatitis A. Am Fam Physician. 2012;86(11):1027–34.
Johnston DE. Special considerations in interpreting liver function tests. Am Fam Physician. 1999;59(8):2223–30.
Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1999;48:1–37.
Updated Recommendations from the ACIP for Use of Hepatitis A Vaccine in Close Contacts of Newly Arriving International Adoptees. MMWR. 2009;58:1–36.
Prevention of Hepatitis A after Exposure to Hepatitis A Virus and in International Travelers: Updated Recommendations of the ACIP. MMWR. 2007;56:1–32.
Raimondo G, Pollicino T, Squadrito G. Clinical virology of hepatitis B virus infection. J Hepatol. 2003;39:S26–30.
Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2001;34:1225–41.
Fattovich G. Natural history of hepatitis B. J Hepatol. 2003;39:S50–8.
European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227–42.
McMahon BJ. Natural history of chronic hepatitis B. Clin Liver Dis. 2010;14:381–96.
Hepatitis B vaccination – United States, 1982–2002. MMWR Morb Mortal Wkly Rep. 2002;51:549–52, 563.
Centers for Disease Control and Prevention. Sexually transmitted disease treatment guidelines. MMWR. 2010;59:1–116.
Centers for Disease Control and Prevention. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part 1. MMWR. 2005;54(RR-16):1–23.
Gitnick G. Non-A, non-B hepatitis: etiology and clinical course. Annu Rev Med. 1984;35:265–78.
Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378(9791):571–83.
Seef LB. Natural history of hepatitis C. Hepatology. 1997;26 suppl 1:21S–8.
Barrera JM, Bruguera M, Ercilla MG, Gil C, Celis R, Gil MP, del Valle Onorato M, Rodes J, Ordinas A. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology. 1995;21(3):639.
Everhart JE, Wright EC, Goodman ZD, et al. Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology. 2010;51(2):585–94.
Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003;38(6):1449–57.
Boursier J, de Ledinghen V, Zarski JP, et al. Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive. Hepatology. 2012;55(1):58–67.
AASLD/ISDA/IAS-USA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Accessed 24 Oct 2014.
Chou R, Barth Cottrell E, Wasson N, Rahman B, Guise JM. Screening for hepatitis C virus infection in adults: a systematic review for the U.S. preventive services task force. Ann Intern Med. 2013;158:101–8.
National Institutes of Health. Management of hepatitis C: 2002. National Institutes of Health consensus conference statement. 10–12 June 2002. http://consensus.nih/gov/2002/2002HepatitisC2002116PDF.pdf. Accessed 24 Oct 2014.
Hepatitis C virus infection. American Academy of Pediatrics. Committee on Infectious Diseases. Pediatrics. 1998;101(3 Pt1):481–5.
Bellentani S, Saccoccio G, Costa G, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. Gut. 1997;41:845–50.
Naveau S, Giraud V, Boretto E, Aubert A, Capron F, Chaput JC. Excess weight risk factor for alcoholic liver disease. Hepatology. 1997;25:108–11.
Cohen SM, Ahn J. Review article: the diagnosis and management of alcoholic hepatitis. Aliment Pharmacol Ther. 2009;30(1):3–13.
Akriviadis E, Botla R, Briggs W, et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119:1637.
Lucey MR, Mathurin P, Morgan TG. Alcoholic hepatitis. N Engl J Med. 2009;360:2758–69.
Moyer VA, Preventive Services Task Force. Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: U.S. preventive services task force recommendation statement. Ann Intern Med. 2013;159(3):210–8.
Kaplowitz N. Drug-induced liver injury. Clin Infect Dis. 2004;38 Suppl 2:S44–8.
Kaplowitz N. Drug-induced liver disorders: implications for drug development and regulation. Drug Saf. 2001;24:483–90.
Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166:1632–41.
Benhamou Y, Bochet M, Di Martino V, et al. for the Multivirc Group. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology. 1999;30:1054–58.
Joshi D, O’Grady J, Dieterich D, Gazzard B, Agarwal K. Increasing burden of liver disease in patients with HIV infection. Lancet. 2011;377:1198–209.
Aranzabal L, Casado JL, Moya J, et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C coinfection. Clin Infect Dis. 2005;40:588–93.
Soriano V, Puoti M, Garcia-Gasco P, et al. Antiretroviral drugs and liver injury. AIDS. 2008;22:1–13.
Crum-Cianflone N, Dilay A, Collins G, et al. Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr. 2009;50:464–73.
Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2007;25:883–9.
World Health Organization, International Agency for Research on Cancer. GLOBOCAN 2008. http://globocan.iarc.fr. Accessed 17 Oct 2014.
Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat database: incidence – SEER 9 Regs research data, Nov 2009 Sub (1973–2007). Bethesda: National Cancer Institute, April 2010.
El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–27.
Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2.
Lok AS, Sterling RK, Everhart JE, HALT-C Trial Group, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010;138:493–502.
Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–36.
Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010;30:61–74.
El Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134:1752–63.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this entry
Cite this entry
O’Gurek, D.T. (2015). Diseases of the Liver. In: Paulman, P., Taylor, R. (eds) Family Medicine. Springer, Cham. https://doi.org/10.1007/978-1-4939-0779-3_97-1
Download citation
DOI: https://doi.org/10.1007/978-1-4939-0779-3_97-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Online ISBN: 978-1-4939-0779-3
eBook Packages: Springer Reference MedicineReference Module Medicine
Publish with us
Chapter history
-
Latest
Diseases of the Liver- Published:
- 08 October 2020
DOI: https://doi.org/10.1007/978-1-4939-0779-3_97-2
-
Original
Diseases of the Liver- Published:
- 16 April 2015
DOI: https://doi.org/10.1007/978-1-4939-0779-3_97-1